Guggenheim Sticks to Their Buy Rating for Phathom Pharmaceuticals (PHAT)
Guggenheim analyst Yatin Suneja reiterated a Buy rating on Phathom Pharmaceuticals (PHAT – Research Report) today and set a price target of $12.00. The company’s shares closed today at $8.92. Confident Investing Starts Here: According to TipRanks, Suneja …